Should this be the case, Trop2 could prove to be a useful biomarker for ErbB3 activation and therapeutic stratification in the setting of recurrent HNSCC, an incurable disease for which treatment options are limited. The gene discussed is TACSTD2; the disease is head and neck squamous cell carcinoma.